Global stocks fell on Monday, with declines in all 11 sectors of the S&P 500, as concerns grew over the rising threat of the coronavirus.

Coronavirus outbreaks have disrupted global supply chains linked to China. According to The Wall Street Journal, some economists estimate that a prolonged Chinese shutdown could cost up to $1 trillion in lost manufacturing output.

Every year several new drugs enter the pharma value chain. The launch of a new therapy or drug means a new treatment option for the patient pool and advancement in people’s quality of life.

The demand for global pharmaceutical packaging reached an estimated $94.2 billion in 2018, according to new research and analysis from The Freedonia Group’s comprehensive study Global Pharmaceutical Packaging.

According to a report from The Business Research Company, the cold chain logistics market, which moves biologics, is growing faster globally than the non-cold-chain logistics market, which transports small molecule drugs. Between 2012 and 2018, the cold-chain logistics market more than doubled in size, while the non-cold-chain logistics market grew by only 36% in comparison.

According to Advances in Biopharmaceutical Technology in China, 2nd Ed, a report from BioPlan Associates, China is making strides in raising its Good Manufacturing Process (GMP) standards as it works to improve its global profile. GMP biopharmaceutical manufacturing has a short history in China, with the first version of guidance issued in 1998. In 2010, China's Ministry of Health released its fourth version of China GMP, with this iteration significantly raising the standards to be met by domestic biopharmaceutical developers.

The total U.S. weight loss industry hit a new peak in 2018, growing 4% to $72 billion. The largest diet companies are shifting direction and changing ownership as Weight Watchers rebrands itself to its new name WW and focuses more on wellness, Jenny Craig is up for sale, NutriSystem gets acquired by Tivity Health, and Slim-Fast is acquired by Glanbia, a multilevel marketing firm.

Many have questioned whether China can move from "the world's factory” for consumer goods, electronics, and commodities, into technologically complex biologics.

It shouldn’t come as a surprise that biopharma in China is growing faster than many in the West have projected. A number of economic and development factors are contributing to this growth. But these have all been evolving for decades. 

So if there is a gap in Western (and in some cases China’s own internal) knowledge about this evolution, it should be put down to simply not paying enough attention.  

The global skincare market is fast growing and expansive, ranging from cosmetic products, to over-the-counter drugs, to prescription drugs. The global dermatology market (OTC and prescription) is vast and evolving quickly with forecasts that indicate a global market of €81.9 billion in 2028, growing significantly from €44.1 billion in 2018. The cosmetic skincare market size was valued at €130 billion in 2016.

The global pharmaceuticals market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to a recent pharma market research report by The Business Research Company.